Friday, September 20, 2019 9:48:51 AM
UUUUUUUUUP she goes again
Recent ACRS News
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/13/2026 01:48:54 AM
- Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference • GlobeNewswire Inc. • 05/08/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:32:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 11:15:28 AM
- Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update • GlobeNewswire Inc. • 05/07/2026 10:59:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/05/2026 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 10:45:19 AM
- Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication f • GlobeNewswire Inc. • 04/28/2026 10:30:00 AM
- Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 • GlobeNewswire Inc. • 04/27/2026 08:45:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 11:46:43 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 11:45:36 AM
- Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference • GlobeNewswire Inc. • 04/08/2026 12:30:00 PM
- Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 • GlobeNewswire Inc. • 03/27/2026 02:10:00 PM
- Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting • GlobeNewswire Inc. • 03/20/2026 03:00:00 PM
- Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis • GlobeNewswire Inc. • 03/18/2026 10:55:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 01:51:15 AM
- Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference • GlobeNewswire Inc. • 03/03/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 09:31:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:15:27 PM
- Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/26/2026 11:58:00 AM
- Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052 • GlobeNewswire Inc. • 02/24/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2026 11:10:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2026 11:08:08 PM
